Skip to main content
. 2021 Feb 11;27:100722. doi: 10.1016/j.ymgmr.2021.100722

Table 1.

Demographic, biological and clinical findings in three reported cases of CEP patients treated by iron depletion therapy.

Characteristics Case #1 Case #2 Case #3
Reference 12 13 present CEP patient
Sex Female Female Female
Age at diagnosis 12 months 25 years 8 years
UROS genotype c.217 T > C / c.311C > T c.172G > A / c.172G > A c.598A > T / c.562-4A > G
UROS variant p.Cys73Arg / p.Ala104Val p.Gly58Ser p.Ser197Gly / p.Gln187_Ter266delins31
UROS enzymatic activity * N.R. 1.7 U/mg Hb/h (N > 6) 2.4 U/mg Hb/h (N > 6)
Clinical and biological findings before treatment Skin photosensitivity + + +
Hemolysis + +
Anemia + (blood transfusion)
Red urine + + +/−
Splenectomy + (25 years old)
Erythrodontia + + +/−
Total urine porphyrins 108,364 μg/24 h § 2642 nmol/mmol creat (N < 25) 3698 nmol/mmol creat (N < 25)
Erythrocyte porphyrins N.R. 8.7 μmol/L RBC (N < 1.2) N.D.
Plasma porphyrins N.R. 289 nmol/L (N < 20) N.D.
Therapeutic management Sun avoidance, supportive measures Splenectomy, transfusion Sun avoidance, supportive measures Sun avoidance, supportive measures
Clinical and biological findings upon iron depletion therapy Age at treatment initiation 32 years 49 years 26 years
Lenght of follow-up 8 months (iron chelation) 23 months 26 months
Skin photosensitivity
Hemolysis
Anemia (transfusion) +/− (no transfusion) - (MCV↓)
Red urine N.R.
Erythrodontia N.R. N.R. +/−
Total urine porphyrins 5896 μg/24 h § 271 nmol/mmol creat (N < 25) 270 nmol/mmol creat (N < 25)
Erythrocyte porphyrins N.R. 7.3 μmol/L RBC (N < 1.2) 6.8 μmol/L RBC (N < 1.2)
Plasma porphyrins N.R. 26 nmol/L (N < 20) N.D.
Clinical outcome Reduced skin photosensitivity Improved QoL Reduced skin photosensitivity Improved QoL Reduced skin photosensitivity Improved QoL

N.R. not reported; N.D. not determined; * UROS enzymatic activity determined in red blood cells; § Normal values are not provided in ref. [12] but are usually <200-300 mg/24 h; MCV mean corpuscular volume, + positive; − negative; QoL Quality of Life (reported by the patient, not formerly measured in all three studies).